If Treat-to-Target Works for Gout, Who Will Implement It in Primary Care?

We read with great interest the editorial by Singh¹ commenting on the study by Mulqueen et al² that showed similar rates of monosodium urate crystal dissolution in joints and tendons during treat-to-target (T2T) urate-lowering therapy (ULT). Dr. Singh eloquently articulates the compelling pathophysiological rationale for T2T: complete tophus resolution on dual-energy computed tomography within 12 months represents "an impressive notable finding" that is "uncommon or rare in chronic medical conditions."¹